Chinese maker of antibiotic active pharmaceutical ingredients, used in both human and animal-health medicines.
Chinese maker of antibiotic active pharmaceutical ingredients, used in both human and animal-health medicines.
Moat: narrow (scale, regulatory licence). Scale antibiotic API production with environmental/regulatory compliance built up over years.
Headquarters: China · Employees: 4,251
Size Guobang Pharma (605507.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.82B, the 1266th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥15.60 on 18 Nov 2026.
Performance Over six months the shares fell 6.3%, against -10.4% for the median peer and -20.0% for the China market (cap-weighted) — 10th highest of 21 in its peer set.
Growth Revenue grew 3.2% over the last twelve months (peer median +7.8%); the operating margin is 12.2% (peer median 15.0%).
Valuation It trades at 15.7× forward earnings against a peer median of 19.4× (8th cheapest of 19).
Price implies For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -13 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 5.4 points above its cost of capital (5.0% WACC).
Next results Next results expected around 12 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥6.13B | CN¥5.99B | CN¥5.87B | CN¥5.34B | CN¥5.70B |
| Revenue growth | — | +2% | +10% | -6% | — |
| Gross profit | CN¥1.73B | CN¥1.46B | CN¥1.37B | CN¥1.17B | CN¥1.49B |
| EBITDA | n/a | CN¥1.39B | CN¥1.27B | CN¥949M | CN¥1.21B |
| Net income | CN¥622M | CN¥821M | CN¥782M | CN¥612M | CN¥921M |
| Free cash flow | CN¥569M | CN¥282M | CN¥287M | -CN¥232M | CN¥214M |
| Capital expenditure | CN¥360M | CN¥278M | CN¥419M | CN¥748M | CN¥803M |
| Total debt | CN¥2.01B | CN¥1.66B | CN¥1.99B | CN¥2.06B | CN¥1.21B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Guobang Pharma 605507.SS | $1.82B | -6% | +3% | 12% | 15.7× | -6.0% |
| Harbin Pharmaceutical 600664.SS | $1.78B | +32% | +2% | 5% | 19.7× | -5.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 605507.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.5% | +0.3% | 11th highest of 21 |
| 6-month return | -6.3% | -10.4% | 10th highest of 21 |
| Distance from 52-week high | -27.1% | -32.8% | 8th highest of 21 |
| Revenue growth (TTM) | +3.2% | +7.8% | 9th lowest of 21 |
| Operating margin | 12.2% | 15.0% | 10th lowest of 21 |
| Forward P/E | 15.7× | 19.4× | 8th cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | -6.0% | 3.3% | 2nd least demanding of 15 |
| Growth delivered (Del g) | +7.4% | +8.1% | 6th lowest of 15 |
| Hurdle (Req g minus delivered) | -13.4 pp | -9.0 pp | 6th least demanding of 15 |
| ROIC minus cost of capital | +5.4 pp | +0.1 pp | 8th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Guobang Pharma 605507.SS | China | $1.82B | -6% | +3% | 12% | 15.7× | -6.0% | +7.4% |
| Shenyang Xingqi Pharmaceutical 300573.SZ | China | $1.83B | -25% | +17% | 33% | 13.0× | 5.4% | +29.1% |
| China National Accord Medicines 000028.SZ | China | $1.81B | -3% | 0% | 2% | 10.8× | -9.5% | +4.2% |
| Zymeworks ZYME | United States | $1.81B | +5% | +98% | 17% | 160.4× | n/a | n/a |
| Ultragenyx Pharmaceutical RARE | United States | $1.81B | -24% | +16% | -64% | 9.6× | n/a | n/a |
| Qingdao Baheal Medical 301015.SZ | China | $1.81B | +2% | -6% | 8% | 21.0× | 10.1% | +5.0% |
| Shenzhen Hepalink Pharmaceutical 002399.SZ | China | $1.80B | -12% | -6% | 8% | 25.8× | -0.7% | +0.5% |
| Dermapharm DMP.DE | Germany | $1.85B | -29% | +2% | 21% | 13.2× | -3.4% | +8.0% |
| United Laboratories International 3933.HK | Hong Kong | $1.80B | -20% | -13% | 5% | 13.0× | 1.2% | +7.8% |
| CSPC Hunan Jingfeng Pharmaceutical 000908.SZ | China | $1.85B | -38% | +5% | -18% | n/a | n/a | n/a |
| Eton Pharmaceuticals ETON | United States | $1.79B | +226% | +101% | 29% | 24.6× | 21.9% | +359.6% |
| Harbin Pharmaceutical 600664.SS | China | $1.78B | +32% | +2% | 5% | 19.7× | -5.3% | +8.2% |
| Cohance Lifesciences COHANCE.NS | India | $1.87B | +7% | +14% | 2% | 96.3× | n/a | n/a |
| Tibet Rhodiola Pharmaceutical 600211.SS | China | $1.87B | -8% | +13% | 27% | 12.5× | -1.2% | +16.7% |
| Agios Pharmaceuticals AGIO | United States | $1.78B | +4% | +214% | -298% | n/a | n/a | n/a |
| Anhui Anke Biotechnology (Group) 300009.SZ | China | $1.88B | -12% | -9% | 30% | 18.1× | 8.0% | +9.3% |
| Pfizer PFIZER.NS | India | $1.88B | -20% | +12% | 34% | 21.9× | 11.2% | +2.4% |
| Alivus Life Sciences ALIVUS.NS | India | $1.90B | +36% | +8% | 31% | 23.8× | 20.1% | +6.2% |
| Shilpa Medicare SHILPAMED.NS | India | $1.91B | +94% | +37% | 21% | 54.3× | n/a | n/a |
| Grand Pharmaceutical 0512.HK | Hong Kong | $1.93B | -25% | +7% | 13% | 9.4× | 1.2% | +14.1% |
| NATCO Pharma NATCOPHARM.NS | India | $1.73B | -27% | -30% | 17% | 19.1× | 20.5% | +19.0% |